Current work focuses on finding and validating putative biomarkers for several rheumatic diseases, including ankylosing spondylitis and lupus nephritis. In the area of AS, biomarkers suggesting a poor prognosis with respect to radiological progression are important, and in lupus nephritis, biomarkers that replace kidney biopsy using non-invasive samples are of particular interest to me.